Nakai Yasushi, Anai Satoshi, Tanaka Nobumichi, Chihara Yoshitomo, Haramoto Masaki, Otani Takeshi, Nakagawa Yoshinori, Hirao Yoshihiko, Konishi Noboru, Fujimoto Kiyohide
Department of Urology, Nara Medical University, Nara, Japan.
Nara Urological Research and Treatment Group, Nara, Japan.
Int J Urol. 2016 Oct;23(10):854-860. doi: 10.1111/iju.13167. Epub 2016 Jul 15.
To investigate the effect of bacillus Calmette-Guérin maintenance therapy on patients with intermediate- and high-risk non-muscle-invasive bladder cancer receiving aggressive complete transurethral resection of bladder tumors standardized by well-trained surgeons.
A total of 95 patients were prospectively enrolled. Patients were diagnosed with multiple or recurrent non-muscle-invasive bladder cancer (Ta and T1), or with carcinoma in situ after complete transurethral resection of bladder tumors. Patients with Ta or T1 tumors without carcinoma in situ received six bacillus Calmette-Guérin instillations as induction therapy. Those with carcinoma in situ underwent eight bacillus Calmette-Guérin instillations as induction therapy. The patients were randomized into maintenance and non-maintenance groups. The maintenance group received intravesical bacillus Calmette-Guérin instillations once a week for 3 weeks at 3, 6, 12 and 18 months after bacillus Calmette-Guérin instillation. The primary end-point was recurrence-free survival.
A total of 88 patients were evaluated. The average follow-up period was 48.3 ± 19.0 months. Five-year recurrence-free survival rates for the maintenance and non-maintenance groups were 80.1% and 79.3%, respectively. Five-year progression-free survival rates of the maintenance and non-maintenance groups were 92.4% and 85.3%, respectively. Recurrence- and progression-free survival rates did not significantly increase in the maintenance group compared with that in the non-maintenance group.
Bacillus Calmette-Guérin maintenance therapy did not improve recurrence- and progression-free survival rates after the initial complete transurethral resection of bladder tumors compared with that after bacillus Calmette-Guérin induction therapy alone.
探讨卡介苗维持治疗对接受由训练有素的外科医生进行的标准积极经尿道膀胱肿瘤完全切除术的中高危非肌层浸润性膀胱癌患者的影响。
前瞻性纳入95例患者。患者被诊断为多发或复发性非肌层浸润性膀胱癌(Ta和T1),或经尿道膀胱肿瘤完全切除术后原位癌。Ta或T1肿瘤且无原位癌的患者接受6次卡介苗灌注作为诱导治疗。原位癌患者接受8次卡介苗灌注作为诱导治疗。患者被随机分为维持治疗组和非维持治疗组。维持治疗组在卡介苗灌注后3、6、12和18个月,每周进行1次膀胱内卡介苗灌注,共3周。主要终点是无复发生存率。
共评估88例患者。平均随访期为48.3±19.0个月。维持治疗组和非维持治疗组的5年无复发生存率分别为80.1%和79.3%。维持治疗组和非维持治疗组的5年无进展生存率分别为92.4%和85.3%。与非维持治疗组相比,维持治疗组的无复发和无进展生存率没有显著提高。
与单独的卡介苗诱导治疗相比,卡介苗维持治疗在初次经尿道膀胱肿瘤完全切除术后并未提高无复发和无进展生存率。